Wolfson Institute for Biomedical Research at the
Menu not loaded, please hit refresh
The Wolfson Institute for Biomedical Research (WIBR) fosters the conversion of scientific results into commercial assets through collaborative projects and spin-out companies as well as consultancy contracts and licensing agreements. Skills in project management, business development and technology exploitation are brought together with the scientific expertise within the WIBR to the academia-industry interface.
The diverse mix of disciplines and experience at the WIBR adds value to every part of the drug discovery process in multiple disease areas. The WIBR has particular strengths in medicinal chemistry, molecular biology, pharmacology and neuroscience. These strengths enable us to add value to projects varying from detailed investigation of the mode of action of a new drug to drug-candidate discovery programmes. The success of all these activities generates revenue which is returned to UCL, the WIBR, and the individual researchers responsible for creation of our intellectual property portfolio.
We have available for licensing a number of patented projects that we actively market at conferences and partnering meetings. Many of these can be seen on here. We also transfer knowledge to the wider community through collaborative projects and spin-out companies.
UCL Business PLC
UCL Business PLC (UCLB) is the contact point for commercialising research, generated from all disciplines within the WIBR and across UCL, through patenting and licensing innovations, engaging consultancy services, and creating spin-outs and joint ventures where appropriate. We:
• Identify and protect promising new technologies and innovations
• Transact commercial activity including options, licences and collaborative commercial research
• Structure spin-out companies and joint ventures where appropriate
• Promote UCL expertise and innovations worldwide
• Offer a single point of contact for business relations with UCL.